Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
PHATFLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
PHATFLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom.
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
PHATFLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates.
Craig-Hallum Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $17
PHATHC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $20 Price Target
PHATPhathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna
PHATPhathom Pharmaceuticals Inc. (NASDAQ: PHAT) shares are trading lower Friday after the company announced a major regulatory win.
Needham Maintains Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
PHATPhathom Pharmaceuticals Shares Resume Trading
PHATPhathom Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 117.1%
PHATPhathom Pharmaceuticals Shares Resume Trade
PHATPhathom Pharmaceuticals Shares Resume Trade Then Again Halt On Circuit Breaker To The Upside, Stock Now Up 127.5%
PHATPhathom Pharmaceuticals Shares Resume Trade Then Again Halt On Circuit Breaker To The Upside, Stock Now Up 80.2%
PHATPhathom Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 59.1%
PHATUPDATE: Watching Phathom Pharmaceuticals; Shares Spike Higher, FDA Has Granted The Co The 10 Year NCE Exclusivity And The Correction To The Orange Book Listings For 10 Mg & 20 Mg Voquezna Tablets To Reflect Full 10-Year NCE Exclusivity Through May 3, 2032
PHATGoldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $5
PHATGuggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $12
PHATHC Wainwright & Co. Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $20
PHATUPDATE: Phathom Pharmaceuticals Q1 Adj. EPS $(1.07) Beats $(1.15) Estimate,
PHATPhathom Pharmaceuticals Q1 EPS $(1.31) Misses $(1.18) Estimate, Sales $28.52M Miss $29.02M Estimate
PHATInsights Ahead: Phathom Pharmaceuticals's Quarterly Earnings
PHATPhathom to Showcase Real-World Data for VOQUEZNA Heartburn Treatment at Major GI Conference
PHATNeedham Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
PHATGoldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $10
PHATNeedham Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
PHATGuggenheim Reiterates Buy on Phathom Pharmaceuticalsto Buy
PHATNeedham Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
PHATKenan Thompson Teams Up with Phathom to Raise Awareness About GERD and New Treatment
PHATForm4 Shows Phathom Pharmaceuticals Director Asit Parikh Purchased 10,000 Shares At Avg. Price $4.42
PHATGoldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $12
PHATHC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
PHATNeedham Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
PHATPhathom Pharmaceuticals Q4 Adj $(0.79) Beats $(1.27) Estimate, Sales $29.66M Beat $24.91M Estimate
PHATNeedham Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
PHATNeedham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
PHAT